JP2024540347A5 - - Google Patents
Info
- Publication number
- JP2024540347A5 JP2024540347A5 JP2024526794A JP2024526794A JP2024540347A5 JP 2024540347 A5 JP2024540347 A5 JP 2024540347A5 JP 2024526794 A JP2024526794 A JP 2024526794A JP 2024526794 A JP2024526794 A JP 2024526794A JP 2024540347 A5 JP2024540347 A5 JP 2024540347A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- cells
- memory
- antibody
- natural killer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163277505P | 2021-11-09 | 2021-11-09 | |
| US63/277,505 | 2021-11-09 | ||
| PCT/US2022/079528 WO2023086810A1 (en) | 2021-11-09 | 2022-11-09 | Combination cancer therapy with memory nk cells and anti-cancer bispecific molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540347A JP2024540347A (ja) | 2024-10-31 |
| JP2024540347A5 true JP2024540347A5 (enExample) | 2025-11-18 |
Family
ID=86336794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526794A Pending JP2024540347A (ja) | 2021-11-09 | 2022-11-09 | 記憶ｎｋ細胞と抗癌性二重特異性分子とによる組み合わせ癌療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240358759A1 (enExample) |
| EP (1) | EP4430081A4 (enExample) |
| JP (1) | JP2024540347A (enExample) |
| KR (1) | KR20240099387A (enExample) |
| CN (1) | CN118215683A (enExample) |
| AU (1) | AU2022386318A1 (enExample) |
| CA (1) | CA3235938A1 (enExample) |
| TW (1) | TW202328202A (enExample) |
| WO (1) | WO2023086810A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250064935A1 (en) * | 2023-07-13 | 2025-02-27 | Sanofi | Natural killer cells and cd123 nk cell engager combination therapy |
| WO2025085525A2 (en) * | 2023-10-17 | 2025-04-24 | Memorial Sloan-Kettering Cancer Center | Combination therapy with cytokine induced memory- like natural killer (cimn) cells and pd-l1 inhibitors to treat relapsed or refractory acute myelogenous leukemia |
| CN117430707B (zh) * | 2023-10-25 | 2024-04-19 | 重庆天科雅生物科技有限公司 | 一种cik细胞的制备方法及其在治疗癌症中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030086922A1 (en) * | 1994-12-02 | 2003-05-08 | David B. Ring | Method of promoting an immune response with a bispecific antibody |
| US8362210B2 (en) * | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
| US10066207B2 (en) * | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| US11471486B2 (en) * | 2012-09-04 | 2022-10-18 | Inven2 As | Selective and controlled expansion of educated NK cells |
| CN109952369B (zh) * | 2016-10-05 | 2024-03-22 | 弗罗里达中央大学研究基金会 | 涉及nk细胞和抗pdl1癌症治疗的方法和组合物 |
| ES3068417T3 (en) * | 2018-09-13 | 2026-05-29 | Nkarta Inc | Natural killer cell compositions and immunotherapy methods for treating a liver tumor |
| EP4426350A4 (en) * | 2021-11-04 | 2025-09-24 | Artiva Biotherapeutics Inc | Treatment of cancer with nk cells and multispecific engagers |
-
2022
- 2022-11-09 CN CN202280074709.9A patent/CN118215683A/zh active Pending
- 2022-11-09 KR KR1020247018183A patent/KR20240099387A/ko active Pending
- 2022-11-09 JP JP2024526794A patent/JP2024540347A/ja active Pending
- 2022-11-09 WO PCT/US2022/079528 patent/WO2023086810A1/en not_active Ceased
- 2022-11-09 TW TW111142722A patent/TW202328202A/zh unknown
- 2022-11-09 CA CA3235938A patent/CA3235938A1/en active Pending
- 2022-11-09 EP EP22893797.5A patent/EP4430081A4/en active Pending
- 2022-11-09 AU AU2022386318A patent/AU2022386318A1/en active Pending
-
2024
- 2024-05-08 US US18/657,954 patent/US20240358759A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115551888B (zh) | 抗cd73抗体及其用途 | |
| RU2019116661A (ru) | Антитела против pd-l1 и их варианты | |
| US12297284B2 (en) | Anti-TNFR2 antibody and use thereof | |
| JP2021184724A (ja) | 液性免疫応答の増強方法 | |
| JP2022002520A5 (enExample) | ||
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2024096688A5 (enExample) | ||
| JP2018512170A5 (enExample) | ||
| JP2019535250A5 (enExample) | ||
| CN108064182A (zh) | 采用抗cd38抗体的联合疗法 | |
| RU2019107134A (ru) | Анти-pd-1 антитела | |
| JP2024531409A5 (enExample) | ||
| US20190016796A1 (en) | Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent | |
| JP2020501598A5 (enExample) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2022543710A (ja) | がんを処置するためのクローディン１８．２に対する抗体と免疫チェックポイント阻害剤を伴う併用療法 | |
| JP2022514734A5 (enExample) | ||
| JP2023525695A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| CN109734805B (zh) | 抗ck20蛋白单克隆抗体、细胞系及其制备方法和应用 | |
| JP2021501575A5 (enExample) | ||
| JP2022512944A5 (enExample) | ||
| JP2025172738A (ja) | Ｅｇｆｒ及びｈｅｒ３を標的とする二重特異性四価抗体 | |
| JP2024524301A5 (enExample) | ||
| JP2023506017A5 (enExample) |